J Korean Acad Child Adolesc Psychiatry.  2008 Oct;19(3):147-155.

Efficacy and Tolerability of Osmotic Release Oral System-Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder According to Comorbid Psychiatric Disorders

• Yoon HJ
• Yook KH
• Jon DI
• Seok JH
• Hong N
• Cho SS
• Hong HJ

Abstract

OBJECTIVES
The purpose of this study was to evaluate the efficacy and tolerability of osmotic release oral systemmethylphenidate (OROS-MPH) in children with attention-deficit hyperactivity disorder (ADHD) and comorbid psychiatric disorders.
METHODS
This was an 8-week open label study of OROS-MPH monotherapy. The subjects were 113 children with ADHD aged 6-12 years. Outcome measures were the Korean version of the parent ADHD Rating Scale (K-ARS), Korean version of the Conners Parent Rating Scale (K-CPRS), Clinical Global Impression-Severity and Clinical Global Impression-Improvement. Side effects were monitored using Barkley's Side Effect Rating Scale. We compared the change-over-time in the mean scores of the outcome measure according to the comorbidity of disruptive behavior disorder, depressive disorder, anxiety disorder, and tic disorder.
RESULTS
The mean K-ARS and K-CPRS scores were significantly decreased, regardless of the comorbidity. The mean doses of OROS-MPH and dropout rate did not differ significantly according to comorbidity. The OROS-MPH was well tolerated, regardless of the comorbidity. However, children with tic disorder reported a higher frequency of tics or nervous movements between the 2nd and 8th week than those without tic disorder.
CONCLUSION
The OROS-MPH is effective for decreasing the symptoms of ADHD, and it is well tolerated, even by patients with comorbid psychiatric disorders.

Keyword

ADHD; OROS-Methylphenidate; Comorbidity; Efficacy; Tolerability

MeSH Terms

Aged
Anxiety Disorders
Attention Deficit and Disruptive Behavior Disorders
Child
Comorbidity
Depressive Disorder
Humans
Outcome Assessment (Health Care)
Parents
Patient Dropouts
Tic Disorders
Tics